Literature DB >> 25721606

Inhibition of BET proteins impairs estrogen-mediated growth and transcription in breast cancers by pausing RNA polymerase advancement.

Surojeet Sengupta1, Michael C Biarnes, Robert Clarke, V Craig Jordan.   

Abstract

Estrogen (E2)-induced transcription requires coordinated recruitment of estrogen receptor α (ER) and multiple factors at the promoter of activated genes. However, the precise mechanism by which this complex stimulates the RNA polymerase II activity required to execute transcription is largely unresolved. We investigated the role of bromodomain (BRD) containing bromodomain and extra-terminal (BET) proteins, in E2-induced growth and gene activation. JQ1, a specific BET protein inhibitor, was used to block BET protein function in two different ER-positive breast cancer cell lines (MCF7 and T47D). Real-time PCR and ChIP assays were used to measure RNA expression and to detect recruitment of various factors on the genes, respectively. Protein levels were measured by Western blotting. JQ1 suppressed E2-induced growth and transcription in both MCF7 and T47D cells. The combination of E2 and JQ1 down-regulated the levels of ER protein in MCF7 cells but the loss of ER was not responsible for JQ1-mediated inhibition of E2 signaling. JQ1 did not disrupt E2-induced recruitment of ER and co-activator (SRC3) at the E2-responsive DNA elements. The E2-induced increase in histone acetylation was also not altered by JQ1. However, JQ1 blocked the E2-induced transition of RNA polymerase II from initiation to elongation by stalling it at the promoter region of the responsive genes upstream of the transcription start site. This study establishes BET proteins as the key mediators of E2-induced transcriptional activation. This adds another layer of complexity to the regulation of estrogen-induced gene activation that can potentially be targeted for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25721606      PMCID: PMC5012544          DOI: 10.1007/s10549-015-3319-1

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  51 in total

1.  Mutual synergistic folding in recruitment of CBP/p300 by p160 nuclear receptor coactivators.

Authors:  Stephen J Demarest; Maria Martinez-Yamout; John Chung; Hongwu Chen; Wei Xu; H Jane Dyson; Ronald M Evans; Peter E Wright
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

Review 2.  The transition from transcriptional initiation to elongation.

Authors:  Joseph T Wade; Kevin Struhl
Journal:  Curr Opin Genet Dev       Date:  2008-02-20       Impact factor: 5.578

3.  BET bromodomain inhibition as a novel strategy for reactivation of HIV-1.

Authors:  Camellia Banerjee; Nancie Archin; Daniel Michaels; Anna C Belkina; Gerald V Denis; James Bradner; Paola Sebastiani; David M Margolis; Monty Montano
Journal:  J Leukoc Biol       Date:  2012-07-16       Impact factor: 4.962

4.  Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions.

Authors:  C S Murphy; J J Pink; V C Jordan
Journal:  Cancer Res       Date:  1990-11-15       Impact factor: 12.701

5.  Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation.

Authors:  E T Alarid; N Bakopoulos; N Solodin
Journal:  Mol Endocrinol       Date:  1999-09

Review 6.  Progression through the RNA polymerase II CTD cycle.

Authors:  Stephen Buratowski
Journal:  Mol Cell       Date:  2009-11-25       Impact factor: 17.970

7.  Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells.

Authors:  S Sengupta; I Obiorah; P Y Maximov; R Curpan; V C Jordan
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

8.  An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol.

Authors:  S Y Jiang; D M Wolf; J M Yingling; C Chang; V C Jordan
Journal:  Mol Cell Endocrinol       Date:  1992-12       Impact factor: 4.102

9.  Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.

Authors:  Teeru Bihani; Scott A Ezell; Brendon Ladd; Shaun E Grosskurth; Anne Marie Mazzola; Mark Pietras; Corinne Reimer; Michael Zinda; Stephen Fawell; Celina M D'Cruz
Journal:  Oncotarget       Date:  2015-02-10

10.  Bromodomain protein BRD4 is required for estrogen receptor-dependent enhancer activation and gene transcription.

Authors:  Sankari Nagarajan; Tareq Hossan; Malik Alawi; Zeynab Najafova; Daniela Indenbirken; Upasana Bedi; Hanna Taipaleenmäki; Isabel Ben-Batalla; Marina Scheller; Sonja Loges; Stefan Knapp; Eric Hesse; Cheng-Ming Chiang; Adam Grundhoff; Steven A Johnsen
Journal:  Cell Rep       Date:  2014-07-10       Impact factor: 9.423

View more
  19 in total

1.  Distinct Roles for BET Family Members in Estrogen Receptor α Enhancer Function and Gene Regulation in Breast Cancer Cells.

Authors:  Shino Murakami; Rui Li; Anusha Nagari; Minho Chae; Cristel V Camacho; W Lee Kraus
Journal:  Mol Cancer Res       Date:  2019-09-24       Impact factor: 5.852

2.  The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma.

Authors:  Hemant K Bid; Doris A Phelps; Linlin Xaio; Denis C Guttridge; Jiayuh Lin; Cheryl London; Laurence H Baker; Xiaokui Mo; Peter J Houghton
Journal:  Mol Cancer Ther       Date:  2016-02-23       Impact factor: 6.261

3.  Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.

Authors:  Yangfeng Li; Jiong Zhao; Lauren M Gutgesell; Zhengnan Shen; Kiira Ratia; Katherine Dye; Oleksii Dubrovskyi; Huiping Zhao; Fei Huang; Debra A Tonetti; Gregory R J Thatcher; Rui Xiong
Journal:  J Med Chem       Date:  2020-06-15       Impact factor: 7.446

4.  Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer.

Authors:  Longchuan Bai; Bing Zhou; Chao-Yie Yang; Jiao Ji; Donna McEachern; Sally Przybranowski; Hui Jiang; Jiantao Hu; Fuming Xu; Yujun Zhao; Liu Liu; Ester Fernandez-Salas; Jing Xu; Yali Dou; Bo Wen; Duxin Sun; Jennifer Meagher; Jeanne Stuckey; Daniel F Hayes; Shunqiang Li; Matthew J Ellis; Shaomeng Wang
Journal:  Cancer Res       Date:  2017-02-16       Impact factor: 12.701

5.  Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma.

Authors:  Surya Nagaraja; Nicholas A Vitanza; Pamelyn J Woo; Kathryn R Taylor; Fang Liu; Lei Zhang; Meng Li; Wei Meng; Anitha Ponnuswami; Wenchao Sun; Jie Ma; Esther Hulleman; Tomek Swigut; Joanna Wysocka; Yujie Tang; Michelle Monje
Journal:  Cancer Cell       Date:  2017-04-20       Impact factor: 31.743

Review 6.  Targeting bromodomain and extraterminal proteins in breast cancer.

Authors:  Jennifer M Sahni; Ruth A Keri
Journal:  Pharmacol Res       Date:  2017-11-16       Impact factor: 7.658

7.  Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.

Authors:  Zhongyuan Gao; Ting Yuan; Xiao Zhou; Ping Ni; Geng Sun; Ping Li; Zhixiang Cheng; Xuerong Wang
Journal:  Cancer Biol Ther       Date:  2018-02-06       Impact factor: 4.742

Review 8.  Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise.

Authors:  Daphné Morel; Daniel Jeffery; Geneviève Almouzni; Sophie Postel-Vinay; Sandrine Aspeslagh
Journal:  Nat Rev Clin Oncol       Date:  2019-09-30       Impact factor: 66.675

9.  Estrogen-Induced Apoptosis in Breast Cancers Is Phenocopied by Blocking Dephosphorylation of Eukaryotic Initiation Factor 2 Alpha (eIF2α) Protein.

Authors:  Surojeet Sengupta; Catherine M Sevigny; Poulomi Bhattacharya; V Craig Jordan; Robert Clarke
Journal:  Mol Cancer Res       Date:  2019-01-17       Impact factor: 5.852

10.  Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells.

Authors:  Gabor Borbely; Lars-Arne Haldosen; Karin Dahlman-Wright; Chunyan Zhao
Journal:  Oncotarget       Date:  2015-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.